Iniparib (BSI-201)

Iniparib, the United States Adopted Name (USAN) for the investigational PARP1 inhibitor, BSI-201, is a potent inhibitor of PARP1, or poly (ADP-ribose) polymerase-1, with first-in-class and best-in-class potential as targeted therapy for several types of cancer. 

Iniparib is being evaluated in multiple Phase 2 and Phase 3 clinical trials in breast, ovarian, uterine, and brain tumors. More than 400 patients have been treated to date with iniparib monotherapy, as well as in combination with chemotherapeutic regimens.

PARP is an established target of cancer therapy. Studies have shown that the inhibition of PARP prevents malignant cells from repairing damaged DNA, ultimately leading to impaired tumor growth and cancer cell death.

Iniparib is a leading candidate in the field of PARP inhibitors and is the furthest along in clinical development of this novel therapeutic approach.

Clinical Status and Recent Milestones of Iniparib